X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (550) 550
index medicus (378) 378
bendamustine hydrochloride (345) 345
female (288) 288
male (286) 286
antineoplastic combined chemotherapy protocols - therapeutic use (271) 271
aged (269) 269
hematology (269) 269
middle aged (268) 268
oncology (268) 268
bendamustine (267) 267
rituximab (227) 227
nitrogen mustard compounds - therapeutic use (196) 196
treatment outcome (165) 165
nitrogen mustard compounds - administration & dosage (164) 164
adult (162) 162
leukemia, lymphocytic, chronic, b-cell - drug therapy (149) 149
chemotherapy (141) 141
aged, 80 and over (129) 129
bendamustine hydrochloride - administration & dosage (121) 121
antineoplastic agents - therapeutic use (120) 120
nitrogen mustard compounds - adverse effects (120) 120
cancer (114) 114
antineoplastic agents (111) 111
antimitotic agents (107) 107
lymphomas (107) 107
antineoplastic combined chemotherapy protocols - adverse effects (101) 101
antineoplastic agents, alkylating - therapeutic use (99) 99
non-hodgkins-lymphoma (98) 98
care and treatment (93) 93
bendamustine hydrochloride - therapeutic use (87) 87
plus rituximab (82) 82
therapy (82) 82
chronic lymphocytic-leukemia (79) 79
lymphoma, non-hodgkin - drug therapy (76) 76
recurrence (73) 73
rituximab - administration & dosage (73) 73
medicine & public health (71) 71
disease-free survival (69) 69
chronic lymphocytic leukemia (66) 66
cyclophosphamide (66) 66
trial (66) 66
antibodies, monoclonal, murine-derived - administration & dosage (65) 65
pharmacology & pharmacy (65) 65
multicenter (63) 63
fludarabine (61) 61
leukemia (60) 60
lymphoma (59) 59
lymphoma, mantle-cell - drug therapy (58) 58
retrospective studies (56) 56
multiple myeloma - drug therapy (55) 55
antineoplastic combined chemotherapy protocols - administration & dosage (53) 53
remission induction (53) 53
antineoplastic agents - adverse effects (52) 52
bortezomib (50) 50
drug administration schedule (49) 49
drug therapy (49) 49
hematology, oncology and palliative medicine (49) 49
toxicity (48) 48
bendamustine hydrochloride - adverse effects (47) 47
lymphoma, b-cell - drug therapy (47) 47
multiple myeloma (47) 47
phase-ii (47) 47
survival (47) 47
1st-line treatment (46) 46
prognosis (46) 46
analysis (45) 45
combination (44) 44
cyclophosphamide - administration & dosage (44) 44
mantle cell lymphoma (44) 44
efficacy (43) 43
neoplasm staging (43) 43
phase-ii multicenter (43) 43
salvage therapy (43) 43
mantle cell (42) 42
rituximab - therapeutic use (41) 41
antineoplastic agents - administration & dosage (40) 40
open-label (40) 40
antineoplastic agents, alkylating - adverse effects (39) 39
clinical trials (39) 39
follow-up studies (39) 39
neoplasm recurrence, local - drug therapy (39) 39
follicular lymphoma (38) 38
in-vitro (38) 38
transplantation (38) 38
vidarabine - analogs & derivatives (38) 38
animals (37) 37
lymphoma, follicular - drug therapy (37) 37
patients (37) 37
relapse (37) 37
thalidomide - analogs & derivatives (37) 37
previously untreated patients (36) 36
survival rate (36) 36
nitrogen mustard compounds - pharmacology (35) 35
phase-ii trial (35) 35
stem-cell transplantation (35) 35
antibodies, monoclonal - therapeutic use (34) 34
antibodies, monoclonal, murine-derived - therapeutic use (34) 34
clinical trials as topic (34) 34
cll (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (552) 552
Japanese (15) 15
German (11) 11
Czech (2) 2
Spanish (2) 2
Chinese (1) 1
French (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 10/2016, Volume 128, Issue 14, pp. 1814 - 1820
Journal Article
Leukemia, ISSN 0887-6924, 10/2016, Volume 30, Issue 10, pp. 2019 - 2025
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 257 - 266
Journal Article
Blood, ISSN 0006-4971, 09/2015, Volume 126, Issue 12, pp. 1407 - 1414
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2017, Volume 176, Issue 4, pp. 618 - 628
Summary Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of malignant B cells and induces... 
CLL | otlertuzumab | bendamustine | ANTIBODIES | DIAGNOSIS | NON-HODGKINS-LYMPHOMAS | QUANTITATIVE FLOW-CYTOMETRY | II TRIAL | CHRONIC LYMPHOPROLIFERATIVE DISORDERS | FLUDARABINE | THERAPY | RITUXIMAB | B-CELL MALIGNANCIES | HEMATOLOGY | Bendamustine Hydrochloride - therapeutic use | Recurrence | Salvage Therapy - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fever - chemically induced | Leukemia, Lymphocytic, Chronic, B-Cell - complications | Bendamustine Hydrochloride - administration & dosage | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Antineoplastic Agents, Alkylating | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Immunoglobulin G - therapeutic use | Immunoglobulin G - administration & dosage | Remission Induction | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Salvage Therapy - methods | Antimitotic agents | Medical research | Care and treatment | Relapse | Medicine, Experimental | B cells | Antineoplastic agents | Hyperthermia | Fever | Diseases | Chronic lymphatic leukemia | Toxicity | Leukemia | Caspase | Cytotoxicity | Patients | Incidence | Infusion | Lymphocytes B | Response rates | Neutropenia | Apoptosis | Antibody-dependent cell-mediated cytotoxicity | Research Paper | Haematological Malignancy
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
Journal Article
Apoptosis, ISSN 1360-8185, 06/2017, Volume 22, Issue 6, pp. 827 - 840
Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis.... 
Bendamustine | Synergistic effect | Lymphoma | Ricolinostat | Apoptosis | MULTIPLE-MYELOMA | MULTICENTER | AGGRESOME FORMATION | ACY-1215 | ACETYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MECHANISMS | CELL BIOLOGY | THIOREDOXIN | IN-VIVO | LENALIDOMIDE | HISTONE DEACETYLASE INHIBITORS | Bendamustine Hydrochloride - therapeutic use | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Histone Deacetylase 6 - metabolism | Lymphoma - drug therapy | Mesenchymal Stromal Cells - cytology | Microtubules - metabolism | Tubulin - metabolism | Caspases - metabolism | Microtubules - drug effects | Interleukin-10 - metabolism | Lymphoma - pathology | Clone Cells | Proto-Oncogene Proteins c-akt - metabolism | Hydroxamic Acids - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Mesenchymal Stromal Cells - drug effects | Endoplasmic Reticulum Stress - drug effects | Histone Deacetylase 6 - antagonists & inhibitors | Cell Cycle Proteins - metabolism | Pyrimidines - pharmacology | Enzyme Activation - drug effects | Drug Synergism | Acetylation - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Bendamustine Hydrochloride - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Proto-Oncogene Proteins c-bcl-2 | Cell Cycle - drug effects
Journal Article